ORIFARM GENERICS A/S: Financial statements 2017
CVR: 25674030
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 171,953,000 and a net result of DKK 76,351,000 compared with DKK 83,250,000 the year before. That is an increase of 1.2% compared with the year before. Equity in the 2017 report amounted to DKK 86,770,000. The solvency ratio was 33.4%. The company had 97 employees in the financial year.
- Gross Profit
- DKK 171,953,000
- Profit/Loss
- DKK 76,351,000
- Equity
- DKK 86,770,000
- Total Assets
- DKK 259,688,000
- Employees
- 97
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 172 mio. | 76.4 mio. | 86.8 mio. | 97 |
| 2016 | - | 169.9 mio. | 83.3 mio. | 60.4 mio. | 78 |
| 2015 | - | 40 mio. | 605 t. | 8 mio. | - |
| 2014 | - | 32.1 mio. | 550 t. | 7.4 mio. | - |
| 2013 | - | 30.7 mio. | 1.3 mio. | 6.9 mio. | - |
Official annual report
Keep an eye on ORIFARM GENERICS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
ORIFARM GENERICS A/S has published its annual report for 2016. Gross profit came to DKK 169,885,000, and the net result was DKK 83,250,000.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.